doi:10.3969/j.issn.1673-8640.2023.09.018

Abstract

CLC Number:

R446.11

Figures/Tables 9

References 15

[1]	夏丽娜. 三种肿瘤标志物联合铁蛋白检测对原发性肝癌的诊断价值分析[J]. 四川解剖学杂志, 2019, 27(1):22-23.
[2]	黄峰, 刘艳芳. 探讨凝血四项指标及肿瘤标志物诊断乙型肝炎相关肝癌的价值[J]. 中国医药科学, 2019, 9(21):165-167.
[3]	GHOSH S, BHOWMIK S, MAJUMDAR S, et al. The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein[J]. Int J Cancer, 2020, 147(10):2934-2947. DOI PMID
[4]	KAEWDECH A, TANGKIJVANICH P, SRIPONGPUN P, et al. Hepatitis B surface antigen,core-related antigen and HBV RNA:predicting clinical relapse after NA therapy discontinuation[J]. Liver Int, 2020, 40(12):2961-2971. DOI URL
[5]	林国桢, 代天星, 刘荣强, 等. 不同肝功能Child-Pugh分级对肝癌肝移植受者预后的影响[J]. 器官移植, 2019, 10(3):308-312.
[6]	ZHANG X, WANG L, YAN Y. Identification of potential key genes and pathways in hepatitis B virus-associated hepatocellular carcinoma by bioinformatics analyses[J]. Oncology Lett, 2020, 19(5):13-14.
[7]	代艳超, 吴云, 张弛, 等. 不同病因肝癌相关肿瘤标志物的研究[J]. 国际病毒学杂志, 2019, 26(1):59-63.
[8]	ZHUANG M, XIN G, WEI Z, et al. Dihydrodiosgenin inhibits endothelial cell-derived factor Ⅷ and platelet-mediated hepatocellular carcinoma metastasis[J]. Cancer Manag Res, 2019, 11:4871-4882. DOI URL
[9]	刘业琼, 邹珍珍, 沈丽娟, 等. 血清异常凝血酶原检测在原发性肝癌临床诊断中的价值分析[J]. 当代临床医刊, 2019, 32(1):28-29.
[10]	XU D, WU J, DONG L, et al. Serpinc1 acts as a tumor suppressor in hepatocellular carcinoma through inducing apoptosis and blocking macrophage polarization in an ubiquitin-proteasome manner[J]. Front Oncol, 2021, 11:738607. DOI URL
[11]	王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析[J]. 实用肝脏病杂志, 2019, 22(1):113-116.
[12]	MORI N, MOTOKI T, MATSUO T, et al. 289. Importance of universal screening for hepatitis B in cancer patients:quality improvement project in Japan[J]. Open Forum Infectious Diseases, 2019, 6(Suppl 2):S157-S158. DOI URL
[13]	WANYAMA F M, TAUBER R, MOKOMBA A, et al. The burden of hepatitis B,hepatitis C,and human immunodeficiency viruses in ovarian cancer patients in Nairobi,Kenya[J]. Infect Dis Rep, 2022, 14(3):443-445.
[14]	HARRIS P S, HANSEN R M, GRAY M E, et al. Hepatocellular carcinoma surveillance:an evidence-based approach[J]. World J Gastroenterol, 2019, 25(13):1550-1559. DOI URL
[15]	刘智鹏, 王明达, 陈志宇, 等. 乙型肝炎相关性肝癌的一级预防[J]. 肝胆外科杂志, 2021, 29(5):341-344.

组别	例数	PT/s	TT/s	APTT/s	Fib/（g/L）
实验组	128	18.66±2.23	25.78±3.21	48.31±3.84	1.67±0.28
对照组	128	13.34±2.36	17.82±2.40	30.55±3.26	2.74±0.31
t值		18.537	22.469	39.950	28.980
P值		<0.001	<0.001	<0.001	<0.001

组别	例数	PT/s	TT/s	APTT/s	Fib/（g/L）
实验组	128	18.66±2.23	25.78±3.21	48.31±3.84	1.67±0.28
对照组	128	13.34±2.36	17.82±2.40	30.55±3.26	2.74±0.31
t值		18.537	22.469	39.950	28.980
P值		<0.001	<0.001	<0.001	<0.001

组别	例数	PT/[例（%）]	TT/[例（%）]	APTT/[例（%）]	Fib/[例（%）]
实验组	128	104（81.25）	96（75.00）	88（68.75）	82（64.06）
对照组	128	36（28.13）	39（30.47）	38（29.69）	26（20.31）
χ²值		72.891	50.918	39.072	50.226
P值		<0.001	<0.001	<0.001	<0.001

组别	例数	PT/[例（%）]	TT/[例（%）]	APTT/[例（%）]	Fib/[例（%）]
实验组	128	104（81.25）	96（75.00）	88（68.75）	82（64.06）
对照组	128	36（28.13）	39（30.47）	38（29.69）	26（20.31）
χ²值		72.891	50.918	39.072	50.226
P值		<0.001	<0.001	<0.001	<0.001

组别	例数	AFP/ （ng/mL）	AFU/ （U/L）	CA724/ （U/mL）
实验组	128	95.84±6.91	77.21±4.78	13.53±1.07
对照组	128	75.42±3.30	44.50±4.63	10.54±0.68
t值		28.692	62.411	26.682
P值		<0.001	<0.001	<0.001

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 15

Related Articles 15

Recommended Articles

Metrics

组别	例数	AFP/ [例（%）]	AFU/ [例（%）]	CA724/ [例（%）]
实验组	128	112（87.50）	104（81.25）	99（77.34）
对照组	128	56（43.75）	53（41.41）	49（38.28）
χ值		54.303	42.840	40.040
P值		<0.001	<0.001	<0.001

项目	AUC^①（95%CI^②）	最佳临界值	标准误	P值	敏感性/%	特异性/%	约登指数
PT	0.765（0.705~0.825）	14 s	0.031	<0.001	81.25	71.88	0.530
TT	0.723（0.659~0.786）	16 s	0.032	<0.001	75.00	69.53	0.445
APTT	0.695（0.630~0.760）	37 s	0.033	<0.001	68.75	70.31	0.391
Fib	0.719（0.655~0.783）	2 g/L	0.033	<0.001	64.06	79.69	0.438

项目	AUC（95%CI）	最佳临界值	标准误	P值	敏感性/%	特异性/%	约登指数
AFP	0.719（0.655~0.783）	40 μg/L	0.033	<0.001	87.50	56.25	0.438
AFU	0.703（0.638~0.768）	35 U/L	0.033	<0.001	81.25	59.38	0.407
CA724	0.612（40.71~61.70）	25 ng/mL	0.036	<0.001	44.32	61.70	0.060

[1]	DENG Chenxia, MEI Yanping, ZHANG Xia, HUANG Baoshan, TIAN Dan, CAO Mengting, HU Yongqi, LIN Yongping, TIAN Lijun. Depolymerization effect of optical platelet count on reversible platelet aggregation after blood collection [J]. Laboratory Medicine, 2023, 38(11): 1087-1090.
[2]	LU Tingyan, GU Danfeng, WANG Yahong, GE Yafang, YANG Haiou. Evaluation of vaginal secretion routine determination modes and review criteria analysis [J]. Laboratory Medicine, 2023, 38(11): 1091-1097.
[3]	. [J]. Laboratory Medicine, 2023, 38(11): 1098-1100.
[4]	. [J]. Laboratory Medicine, 2023, 38(10): 983-986.
[5]	CHENG Xu, YANG Cunqing, PANG Bo, GU Chun, HOU Xueyun, FEI Jiaxin, WU Min, LI Jun, LIU Guijian. Number and activity of peripheral blood eosinophils in obese people [J]. Laboratory Medicine, 2023, 38(9): 855-859.
[6]	LEI Jing, MAN Qiuhong, ZHAO Renjia, ZHANG Tiejun, JIANG Yanfeng, XU Kelin, SUO Chen, CHEN Xingdong. Elevated red blood cell distribution width increasing the risk of heart failure：a cohort study based on the UK Biobank [J]. Laboratory Medicine, 2023, 38(9): 860-864.
[7]	. [J]. Laboratory Medicine, 2023, 38(9): 905-908.
[8]	DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674.
[9]	XIA Yanyan, XIA Yongquan, SONG Guanghao, XIA Mao. Role of coagulation-related monitoring indicators in the course of rivaroxaban anticoagulation for acute venous thromboembolism in elderly patients [J]. Laboratory Medicine, 2023, 38(5): 475-478.
[10]	CHEN Yi, WANG Jia, XU Zhiwei, ZHAI Yaping, XUAN Weixia. Effects of different anticoagulants on phagocytosis，activation and apoptosis of in vitro neutrophil function [J]. Laboratory Medicine, 2023, 38(5): 479-483.
[11]	YANG Liyuan, DAI Wanqin, WANG Xiaotong, LOU Xiaoli, WANG Yue, HOU Yanqiang. Effect of peripheral blood neutrophils on interferon-gamma release assay of Mycobacterium tuberculosis [J]. Laboratory Medicine, 2023, 38(5): 484-488.
[12]	. [J]. Laboratory Medicine, 2023, 38(5): 502-504.
[13]	. [J]. Laboratory Medicine, 2023, 38(1): 69-72.
[14]	XIE Yuan, YI Wanwan, SHI Qiuyuan, LÜ Zhongwei, LIU Jin. Clinical value of thromboelastography and conventional coagulation tests in evaluating coagulation status of colon cancer and colon polyps [J]. Laboratory Medicine, 2022, 37(11): 1007-1011.
[15]	MIAO Wenjia, GU Hao, LI Gang. Clinical application of maximum aggregation rate and thrombus maximum amplitude in children with Glanzmann thrombasthenia and Bernard-Soulier syndrome [J]. Laboratory Medicine, 2022, 37(11): 1026-1029.